ArticleJournal for immunotherapy of cancer2021

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab.

Yoshinobu Koguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.